Background and objective Gefitinib is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has been widely used for the treatment of non-small cell lung cancer (NSCLC). It is most effective in women. as well as in patients who have never smoked. have pulmonary adenocarcinomas. https://www.roneverhart.com/Swordback-Hold-Europe-Ladder/